Literature DB >> 35527415

[Association between duration of fever before treatment and intravenous immunoglobulin resistance in Kawasaki disease].

Xin Wang1, Si-Lin Pan1, Zhan-Hui DU1, Zhi-Xian Ji1, Gang Luo1, Hong-Xiao Sun1, Shu-Jing Ma1.   

Abstract

OBJECTIVES: To examine the association between duration of fever before intravenous immunoglobulin (IVIG) treatment and IVIG resistance in children with Kawasaki disease (KD).
METHODS: A retrospective analysis was performed on the medical data of 317 children with KD who were admitted from January 2018 to December 2020. According to the duration of fever before IVIG treatment, they were divided into two groups: short fever duration group (≤4 days) with 92 children and long fever duration group (>4 days) with 225 children. According to the presence or absence of IVIG resistance, each group was further divided into a drug-resistance group and a non-drug-resistance group. Baseline data and laboratory results were compared between groups. A multivariate logistic regression analysis was used to identify the influencing factors for IVIG resistance.
RESULTS: In the short fever duration group, 19 children (20.7%) had IVIG resistance and 5 children (5.4%) had coronary artery aneurysm, and in the long fever duration group, 22 children (9.8%) had IVIG resistance and 19 children (8.4%) had coronary artery aneurysm, suggesting that the short fever duration group had a significantly higher rate of IVIG resistance than the long fever duration group (P<0.05), while there was no significant difference in the incidence rate of coronary artery aneurysm between the two groups (P>0.05). In the short fever duration group, compared with the children without drug resistance, the children with drug resistance had a significantly lower level of blood sodium and significantly higher levels of procalcitonin, C-reactive protein, and N-terminal B-type natriuretic peptide before treatment (P<0.05). In the long fever duration group, the children with drug resistance had significantly lower levels of blood sodium and creatine kinase before treatment than those without drug resistance (P<0.05). The multivariate logistic regression analysis showed that a reduction in blood sodium level was associated with IVIG resistance in the long fever duration group (P<0.05).
CONCLUSIONS: IVIG resistance in children with KD varies with the duration of fever before treatment. A reduction in blood sodium is associated with IVIG resistance in KD children with a duration of fever of >4 days before treatment.

Entities:  

Keywords:  Child; Drug resistance; Duration of fever; Intravenous immunoglobulin; Kawasaki disease; Risk factor

Mesh:

Substances:

Year:  2022        PMID: 35527415      PMCID: PMC9044994          DOI: 10.7499/j.issn.1008-8830.2110137

Source DB:  PubMed          Journal:  Zhongguo Dang Dai Er Ke Za Zhi        ISSN: 1008-8830


  21 in total

1.  Prediction of intravenous immunoglobulin unresponsiveness in patients with Kawasaki disease.

Authors:  Tohru Kobayashi; Yoshinari Inoue; Kazuo Takeuchi; Yasunori Okada; Kazushi Tamura; Takeshi Tomomasa; Tomio Kobayashi; Akihiro Morikawa
Journal:  Circulation       Date:  2006-05-30       Impact factor: 29.690

Review 2.  JCS/JSCS 2020 Guideline on Diagnosis and Management of Cardiovascular Sequelae in Kawasaki Disease.

Authors:  Ryuji Fukazawa; Junjiro Kobayashi; Mamoru Ayusawa; Hiromichi Hamada; Masaru Miura; Yoshihide Mitani; Etsuko Tsuda; Hiroyuki Nakajima; Hiroyuki Matsuura; Kazuyuki Ikeda; Kazuhiko Nishigaki; Hiroyuki Suzuki; Kei Takahashi; Kenji Suda; Hiroshi Kamiyama; Yoshihiro Onouchi; Tohru Kobayashi; Hiroyoshi Yokoi; Kisaburo Sakamoto; Masami Ochi; Soichiro Kitamura; Kenji Hamaoka; Hideaki Senzaki; Takeshi Kimura
Journal:  Circ J       Date:  2020-07-08       Impact factor: 2.993

3.  Prediction of non-responsiveness to standard high-dose gamma-globulin therapy in patients with acute Kawasaki disease before starting initial treatment.

Authors:  Tetsuya Sano; Shunji Kurotobi; Kouji Matsuzaki; Takehisa Yamamoto; Ichiro Maki; Kazunori Miki; Shigetoyo Kogaki; Junichi Hara
Journal:  Eur J Pediatr       Date:  2006-08-01       Impact factor: 3.183

4.  Inflammasome activation by cell volume regulation and inflammation-associated hyponatremia: A vicious cycle.

Authors:  J H Kim; J H Park; M Eisenhut; J W Yu; J I Shin
Journal:  Med Hypotheses       Date:  2016-05-18       Impact factor: 1.538

5.  A New Scoring System for Prediction of Intravenous Immunoglobulin Resistance of Kawasaki Disease in Infants Under 1-Year Old.

Authors:  Shu Wu; Yuan Long; Selena Chen; Yaqian Huang; Ying Liao; Yan Sun; Qingyou Zhang; Chunyu Zhang; Hui Yan; Jianguang Qi; Xueqin Liu; Yonghong Chen; Yong Zhang; Junbao Du
Journal:  Front Pediatr       Date:  2019-12-11       Impact factor: 3.418

6.  Prediction of repeated intravenous immunoglobulin resistance in children with Kawasaki disease.

Authors:  Yaheng Lu; Tingting Chen; Yizhou Wen; Feifei Si; Xindan Wu; Yanfeng Yang
Journal:  BMC Pediatr       Date:  2021-09-16       Impact factor: 2.125

7.  Serum sodium level associated with coronary artery lesions in patients with Kawasaki disease.

Authors:  Hiroya Masuda; Ryusuke Ae; Taka-Aki Koshimizu; Masami Matsumura; Koki Kosami; Kanako Hayashida; Nobuko Makino; Yuri Matsubara; Teppei Sasahara; Yosikazu Nakamura
Journal:  Clin Rheumatol       Date:  2021-08-07       Impact factor: 2.980

8.  A Retrospective Cohort Study of Intravenous Immunoglobulin Therapy in the Acute Phase of Kawasaki Disease: The Earlier, the Better?

Authors:  Wei Li; Xiufang He; Li Zhang; Zhouping Wang; Yanfei Wang; Huimei Lin; Jia Yuan; Xiaofei Xie; Youzhen Qin; Ping Huang
Journal:  Cardiovasc Ther       Date:  2021-06-18       Impact factor: 3.023

9.  Meta-analysis of factors predicting resistance to intravenous immunoglobulin treatment in patients with Kawasaki disease.

Authors:  Jin-Young Baek; Min Seob Song
Journal:  Korean J Pediatr       Date:  2016-02-29

10.  Blood Mercury Levels in Children with Kawasaki Disease and Disease Outcome.

Authors:  Ling-Sai Chang; Jia-Huei Yan; Jin-Yu Li; Deniz Des Yeter; Ying-Hsien Huang; Mindy Ming-Huey Guo; Mao-Hung Lo; Ho-Chang Kuo
Journal:  Int J Environ Res Public Health       Date:  2020-05-25       Impact factor: 3.390

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.